Charles River Laboratories (CRL) continues to gain from the CRADL initiative. However, the competitive landscape is a concern. The stock carries a Zacks Rank #3 (Hold) currently.Research Models and Services (RMS) business services are in high demand among Charles River’s clients in the field of basic research and screening of non-clinical drug candidates. The RMS segment continues to benefit from broad-based growth in all geographic regions for small research models. Through most of 2023, the company witnes ...